We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Revance Therapeutics Inc (RVNC) USD0.001

Sell:$13.17 Buy:$13.19 Change: $0.60 (4.36%)
Market closed |  Prices as at close on 23 May 2022 | Switch to live prices |
Change: $0.60 (4.36%)
Market closed |  Prices as at close on 23 May 2022 | Switch to live prices |
Change: $0.60 (4.36%)
Market closed |  Prices as at close on 23 May 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Revance Therapeutics, Inc. is a commercial stage biotechnology company. The Company is focused on advanced aesthetic and therapeutic offerings, including neuromodulator product, DaxibotulinumtoxinA for Injection. The DaxibotulinumtoxinA for Injection combines a proprietary stabilizing peptide excipient with a purified botulinum toxin that does not contain human or animal-based components. The Company is also evaluating additional aesthetic and therapeutic indications for DaxibotulinumtoxinA for Injection including the full upper face, which includes glabellar lines, forehead lines and crow’s feet, and adult upper limb spasticity. It offers products and services for United States aesthetics practices, including the resilient hyaluronic acid (RHA) Collection of dermal fillers and OPUL. The RHA Collection of dermal fillers is a dermal filler for the correction of dynamic facial wrinkles and folds. OPUL’s product offering includes the point-of-sale platform, software and hardware terminal.

Contact details

1222 Demonbreun Street, Suite 2000
United States
+1 (615) 7247755

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$1.00 billion
Shares in issue:
72.77 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • Dustin Sjuts
  • Mark Foley
    Chief Executive Officer, Director
  • Tobin Schilke
    Chief Financial Officer
  • Dwight Moxie
    Senior Vice President, General Counsel, Corporate Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.